Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all cause mortality
Experimental evidence has shown potential cardioprotective actions of phosphodiesterase type-5 inhibitors (PDE5is). We investigated whether phosphodiesterase type-5 inhibitor (PDE5i) use in patients with type 2 diabetes, with high attendant cardiovascular risk, was associated with altered mortality in a retrospective cohort study.
Research Design and Methods
Between January 2007 and May 2015, 5,956 men aged 40-89 years diagnosed with type 2 diabetes before 200...
- Publication status:
- Peer review status:
- Peer reviewed
- Publisher's version
- Copyright holder:
- Anderson et al.
- Copyright date:
- Copyright Article author (or their employer) 2016. Produced by BMJ Publishing Group Ltd (& BCS) under licence. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license.